

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Per Sauerberg et al.Application No./Patent No.: 10/734,368Filed/Issue Date: December 12, 2003Entitled: NOVEL COMPOUNDS, THEIR PREPARATION AND USEHigh Point Pharmaceuticals, LLC, a company
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Per Sauerberg et al. To: Novo Nordisk A/SThe document was recorded in the United States Patent and Trademark Office at
Reel 015616, Frame 0143, or for which a copy thereof is attached.2. From: Novo Nordisk A/S To: TransTech Pharma, Inc.The document was recorded in the United States Patent and Trademark Office at
Reel 021018, Frame 0022, or for which a copy thereof is attached.3. From: TransTech Pharma, Inc. To: High Point Pharmaceuticals, LLCThe document was recorded in the United States Patent and Trademark Office at
Reel 021754, Frame 0886, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Anne L. Showalter
Signature5-28-09

Date

Anne L. Showalter336-841-0300

Printed or Typed Name

Telephone Number

Secretary

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

6 3 4 5

STATEMENT UNDER 37 CFR 3.73(b)

Supplemental Sheet – PTO/SB/96

Applicant/Patent Owner: Per Sauerberg et al.

Application No./Patent No.: 10/734,368

Filed/Issue Date: December 12, 2003

Entitled: **NOVEL COMPOUNDS, THEIR PREPARATION AND USE**

4. From: Novo Nordisk A/S To: TransTech Pharma, Inc.

The document was recorded in the United States Patent and Trademark Office at

Reel 022562, Frame 0346, or for which a copy thereof is attached.

5. From: TransTech Pharma, Inc. To: High Point Pharmaceuticals, LLC

The document was recorded in the United States Patent and Trademark Office at

Reel 022584, Frame 0953, or for which a copy thereof is attached.